Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Athersys
Athersys
Activities:
Pharmaceutical
Cell & Gene Therapy
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Cell Therapy Catapult signs multiple collaboration agreements
With the aim of accelerating the development of regenerative medicine
Research & Development
Athersys and Chugai link up to develop MultiStem cell therapy for ischemic stroke in Japan
Athersys will receive an upfront cash payment of US$10m from Chugai
Research & Development
CT Catapult to work with US biopharmaceutical company Athersys
On projects to advance European development of MultiStem therapy
Subscribe now